Genus plc (LON:GNS - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,772.79 ($23.67) and traded as high as GBX 2,090 ($27.91). Genus shares last traded at GBX 2,084.24 ($27.83), with a volume of 123,946 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Shore Capital reissued a "buy" rating on shares of Genus in a research note on Wednesday, April 30th.
View Our Latest Stock Report on Genus
Genus Price Performance
The business has a 50-day simple moving average of GBX 1,805.17 and a two-hundred day simple moving average of GBX 1,772.79. The company has a quick ratio of 1.08, a current ratio of 1.80 and a debt-to-equity ratio of 53.12. The stock has a market capitalization of £1.30 billion, a price-to-earnings ratio of 165.16, a P/E/G ratio of 2.87 and a beta of 0.37.
Genus (LON:GNS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported GBX 39.80 ($0.53) EPS for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. As a group, research analysts predict that Genus plc will post 70.9644323 earnings per share for the current fiscal year.
Insider Buying and Selling at Genus
In other Genus news, insider Jorgen Kokke sold 19,967 shares of the company's stock in a transaction on Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($23.11), for a total value of £345,628.77 ($461,515.25). 0.75% of the stock is owned by corporate insiders.
About Genus
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
